FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:22-26 July 1, 1999 Number 1 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Hepatitis B virus (HBV) infections in patients who lack detectable hepatitis B surface antigen (HBsAg) are called occult infections. Although such infections have been identified in patients with chronic hepatitis C liver disease, their prevalence and clinical significance are not known.

Methods With the polymerase chain reaction, we searched for HBV DNA in liver and serum samples from 200 HBsAg-negative patients with hepatitis C virus (HCV)–related liver disease (147 with chronic hepatitis, 48 with cirrhosis, and 5 with minimal histologic changes). One hundred of the patients had detectable antibodies to the HBV core antigen (anti-HBc); 100 were negative for all HBV markers. Eighty-three were treated with interferon alfa. We also studied 50 patients with liver disease who were negative both for HBsAg and for HCV markers. In six patients found to have occult HBV infection, we evaluated possible genomic rearrangements through cloning or direct sequencing procedures.

Results Sixty-six of the 200 patients with chronic hepatitis C liver disease (33 percent) had HBV sequences, as did 7 of the 50 patients with liver disease unrelated to hepatitis C (14 percent, P=0.01). Among the 66 patients, 46 were anti-HBc–positive and 20 were negative for all HBV markers (P<0.001). Twenty-two of these 66 patients (33 percent) had cirrhosis, as compared with 26 of the 134 patients with hepatitis C infection but no HBV sequences (19 percent, P=0.04). HBV sequences were detected in 26 of the 55 patients in whom interferon therapy was ineffective and 7 of the 28 patients in whom interferon therapy was effective (P=0.06). None of the sequenced HBV genomes had changes known to interfere with viral activity and gene expression.

Conclusions Occult hepatitis B infection occurs frequently in patients with chronic hepatitis C liver disease and may have clinical significance.

Source Information

From the Dipartimento di Medicina Interna, Università di Messina, Messina, Italy.

Address reprint requests to Dr. Raimondo at the Dipartimento di Medicina Interna, Policlinico Universitario, 98100 Messina, Italy, or at raimondo{at}imeuniv.unime.it.

Full Text of this Article

This article has been cited by other articles:

• Hassan, M. M., Li, D., El-Deeb, A. S., Wolff, R. A., Bondy, M. L., Davila, M., Abbruzzese, J. L. (2008). Association Between Hepatitis B Virus and Pancreatic Cancer. JCO 26: 4557-4562 [Abstract] [Full Text]  
• Ramia, S, Mokhbat, J, Ramlawi, F, El-Zaatari, M (2008). Occult hepatitis B virus infection in HIV-infected Lebanese patients with isolated antibodies to hepatitis B core antigen. Int J STD AIDS 19: 197-199 [Abstract] [Full Text]  
• Persico, E, De Renzo, A, La Mura, V, Bruno, S, Masarone, M, Torella, R, Persico, M (2007). Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients. Gut 56: 1470-1471 [Full Text]  
• Guo, H., Zhou, T., Jiang, D., Cuconati, A., Xiao, G.-H., Block, T. M., Guo, J.-T. (2007). Regulation of Hepatitis B Virus Replication by the Phosphatidylinositol 3-Kinase-Akt Signal Transduction Pathway. J. Virol. 81: 10072-10080 [Abstract] [Full Text]  
• Ikeda, K., Marusawa, H., Osaki, Y., Nakamura, T., Kitajima, N., Yamashita, Y., Kudo, M., Sato, T., Chiba, T. (2007). Antibody to Hepatitis B Core Antigen and Risk for Hepatitis C-Related Hepatocellular Carcinoma: A Prospective Study. ANN INTERN MED 146: 649-656 [Abstract] [Full Text]  
• Allice, T., Cerutti, F., Pittaluga, F., Varetto, S., Gabella, S., Marzano, A., Franchello, A., Colucci, G., Ghisetti, V. (2007). COBAS AmpliPrep-COBAS TaqMan Hepatitis B Virus (HBV) Test: a Novel Automated Real-Time PCR Assay for Quantification of HBV DNA in Plasma. J. Clin. Microbiol. 45: 828-834 [Abstract] [Full Text]  
• Comar, M, Dal Molin, G, D'Agaro, P, Croce, S L, Tiribelli, C, Campello, C (2006). HBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. J. Clin. Pathol. 59: 526-529 [Abstract] [Full Text]  
• Rodriguez-Inigo, E., Bartolome, J., Ortiz-Movilla, N., Platero, C., Lopez-Alcorocho, J. M., Pardo, M., Castillo, I., Carreno, V. (2005). Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Can Coinfect the Same Hepatocyte in the Liver of Patients with Chronic HCV and Occult HBV Infection. J. Virol. 79: 15578-15581 [Abstract] [Full Text]  
• Le Mire, M. F., Miller, D. S., Foster, W. K., Burrell, C. J., Jilbert, A. R. (2005). Covalently Closed Circular DNA Is the Predominant Form of Duck Hepatitis B Virus DNA That Persists following Transient Infection. J. Virol. 79: 12242-12252 [Abstract] [Full Text]  
• Rumi, M G, De Filippi, F, La Vecchia, C, Donato, M F, Gallus, S, Del Ninno, E, Colombo, M (2005). Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 54: 402-406 [Abstract] [Full Text]  
• Ryder, S D (2004). Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 53: 451-455 [Abstract] [Full Text]  
• Michalak, T. I., Mulrooney, P. M., Coffin, C. S. (2004). Low Doses of Hepadnavirus Induce Infection of the Lymphatic System That Does Not Engage the Liver. J. Virol. 78: 1730-1738 [Abstract] [Full Text]  
• Dai, C-Y, Yu, M-L, Chen, S-C, Lin, Z-Y, Hsieh, M-Y, Wang, L-Y, Tsai, J-F, Chuang, W-L, Chang, W-Y (2004). Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan. J. Clin. Pathol. 57: 141-145 [Abstract] [Full Text]  
• Goncales, F. L. Jr., Pereira, J. S. F., da Silva, C., Thomaz, G. R., Pavan, M. H. P., Fais, V. C., Magna, L. A., Goncales, N. S. L. (2003). Hepatitis B Virus DNA in Sera of Blood Donors and of Patients Infected with Hepatitis C Virus and Human Immunodeficiency Virus. CVI 10: 718-720 [Abstract] [Full Text]  
• Santagostino, E., Colombo, M., Rivi, M., Rumi, M. G., Rocino, A., Linari, S., Mannucci, P. M. (2003). A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 102: 78-82 [Abstract] [Full Text]  
• Lum, P. J., Ochoa, K. C., Hahn, J. A., Page Shafer, K., Evans, J. L., Moss, A. R. (2003). Hepatitis B Virus Immunization Among Young Injection Drug Users in San Francisco, Calif: The UFO Study. Am. J. Public Health 93: 919-923 [Full Text]  
• Kao, J.-H., Chen, P.-J., Lai, M.-Y., Chen, D.-S. (2002). Occult Hepatitis B Virus Infection and Clinical Outcomes of Patients with Chronic Hepatitis C. J. Clin. Microbiol. 40: 4068-4071 [Abstract] [Full Text]  
• Goedert, J. J., Eyster, M. E., Lederman, M. M., Mandalaki, T., de Moerloose, P., White, G. C. II, Angiolillo, A. L., Luban, N. L. C., Sherman, K. E., Manco-Johnson, M., Preiss, L., Leissinger, C., Kessler, C. M., Cohen, A. R., DiMichele, D., Hilgartner, M. W., Aledort, L. M., Kroner, B. L., Rosenberg, P. S., Hatzakis, A. (2002). End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 100: 1584-1589 [Abstract] [Full Text]  
• Al-Mekhaizeem, K. A., Miriello, M., Sherker, A. H. (2001). The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. CMAJ 165: 1063-1064 [Full Text]  
• Su, Q., Wang, S.-F., Chang, T.-E., Breitkreutz, R., Hennig, H., Takegoshi, K., Edler, L., Schroder, C. H. (2001). Circulating Hepatitis B Virus Nucleic Acids in Chronic Infection : Representation of Differently Polyadenylated Viral Transcripts during Progression to Nonreplicative Stages. Clin. Cancer Res. 7: 2005-2015 [Abstract] [Full Text]  
• Mohsen, A H, Group, T. H. S. (2001). The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 48: 707-713 [Abstract] [Full Text]  
• Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., Seeff, L. B. (2000). Diagnosis and Monitoring of Hepatic Injury. I. Performance Characteristics of Laboratory Tests. Clin. Chem. 46: 2027-2049 [Abstract] [Full Text]  
• KINGHAM, J G C (2000). Dissecting out crytogenic liver disease. Gut 47: 328-329 [Full Text]  
• Berasain, C, Betes, M, Panizo, A, Ruiz, J, Herrero, J I, Civeira, M-P, Prieto, J (2000). Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 47: 429-435 [Abstract] [Full Text]  
• DUSHEIKO, G, BARNES, E, WEBSTER, G, WHALLEY, S (2000). The science, economics, and effectiveness of combination therapy for hepatitis C. Gut 47: 159-161 [Full Text]  
• (1999). Occult Hepatitis B with Hepatitis C. JWatch Infect. Diseases 1999: 8-8 [Full Text]